<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0213264</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1117</journal-id>
<journal-id journal-id-type="nlm-ta">Biol Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Biol. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Biological psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-3223</issn>
<issn pub-type="epub">1873-2402</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29246437</article-id>
<article-id pub-id-type="pmc">6415524</article-id>
<article-id pub-id-type="doi">10.1016/j.biopsych.2017.10.023</article-id>
<article-id pub-id-type="manuscript">NIHMS1006304</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>(−)-P7C3-S243 protects a rat model of Alzheimer’s disease from neuropsychiatric deficits and neurodegeneration without altering amyloid deposition or reactive glia.</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Voorhees</surname>
<given-names>Jaymie R</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Remy</surname>
<given-names>Matthew T</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cintrón-Pérez</surname>
<given-names>Coral J</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>El Rassi</surname>
<given-names>Eli</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kahn</surname>
<given-names>Michael Z</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dutca</surname>
<given-names>Laura M</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yin</surname>
<given-names>Terry C</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McDaniel</surname>
<given-names>Latisha M</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Williams</surname>
<given-names>Noelle S</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brat</surname>
<given-names>Dan J</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pieper</surname>
<given-names>Andrew A</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Psychiatry, University of Iowa Carver College of Medicine Iowa City, IA, USA</aff>
<aff id="A2"><label>2</label>Interdisciplinary Graduate Program in Human Toxicology, University of Iowa Carver College of Medicine Iowa City, IA, USA</aff>
<aff id="A3"><label>3</label>The Iowa City Department of Veterans Affairs Center for the Prevention and Treatment of Visual Loss, Iowa City, Iowa, United States Departments of Ophthalmology and Visual Sciences, The University of Iowa, Iowa City, IA, USA</aff>
<aff id="A4"><label>4</label>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA</aff>
<aff id="A5"><label>5</label>Departments of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA</aff>
<aff id="A6"><label>6</label>Department of Neurology, University of Iowa Carver College of Medicine Iowa City, IA, USA; Department of Free Radical and Radiation Biology Program, University of Iowa Carver College of Medicine Iowa City, IA, USA; Department of Radiation Oncology Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, IA, USA; Department of Veteran Affairs, University of Iowa Carver College of Medicine Iowa City, IA, USA; Pappajohn Biomedical Institute, Iowa Neuroscience Institute, University of Iowa Carver College of Medicine, Iowa City, IA, USA; Weill Cornell Autism Research Program, Weill Cornell Medical College New York, NY, USA</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Correspondence to: Andrew A. Pieper, MD PhD, Department of Psychiatry, University of Iowa Carver College of Medicine, Pappajohn Biomedical Institute, 169 Newton Road, Iowa City, IA 52242, <email>Andrew-Pieper@uiowa.edu</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P29">Financial Disclosures</p>
<p id="P30">Andrew Pieper is co-founder and consultant of Neuroprotective Therapeutics, and holds patents related to the P7C3 series of neuroprotective compounds. JR Voorhees, MT Remy, CJ Cintrón-Pérez, E El Rassi, MZ Kahn, LM Dutca, TC Yin, LM McDaniel, NS Williams, and DJ Brat have no biomedical financial interests or potential conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>14</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>06</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<day>01</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>13</day>
<month>3</month>
<year>2019</year>
</pub-date>
<volume>84</volume>
<issue>7</issue>
<fpage>488</fpage>
<lpage>498</lpage>
<!--elocation-id from pubmed: 10.1016/j.biopsych.2017.10.023-->
<abstract id="ABS1">
<sec id="S1">
<title>Background:</title>
<p id="P1">In addition to cognitive deficits, Alzheimer’s disease (AD) is also associated with other neuropsychiatric symptoms, including severe depression. Indeed, depression often precedes cognitive deficits in patients with AD. Unfortunately, the field has seen only minimal therapeutic advances, underscoring the critical need for new treatments. P7C3 aminopropyl carbazoles promote neuronal survival by enhancing nicotinamide adenine dinucleotide flux in injured neurons. Neuroprotection with P7C3 compounds has been demonstrated in preclinical models of neurodegeneration by virtue of promoting neuronal survival independently of early disease-specific pathology, resulting in protection from cognitive deficits and depressive-like behavior. We hypothesize that P7C3 compounds might thus be uniquely applicable to patients with AD, given the co-morbid presentation of depression and cognitive deficits.</p>
</sec>
<sec id="S2">
<title>Methods:</title>
<p id="P2">Aging male and female wild-type and TgF344-AD rats, a well-characterized preclinical AD model, were administered daily (−)-P7C3-S243 for 9 and 18 months, beginning at 6 months of age. Behavioral phenotypes related to cognition and depression were assessed at 15 and 24 months, and brain pathology and biochemistry were assessed at 24 months.</p>
</sec>
<sec id="S3">
<title>Results:</title>
<p id="P3">(−)-P7C3-S243 safely protected aging male and female wild-type and TgF344-AD rats from cognitive deficits and depressive-like behavior. Depressive-like behavior occurred earlier than cognitive deficits in TgF344-AD rats, consistent with AD in many patients. Treatment with (−)-P7C3-S243 blocked neurodegeneration in TgF344-AD rats, without altering amyloid deposition or indicators of neuroinflammation.</p>
</sec>
<sec id="S4">
<title>Conclusions:</title>
<p id="P4">Neuronal cell death-specific treatment approaches, such as offered by P7C3 compounds, may represent a new treatment approach for patients suffering from the combination of cognitive deficits and depression associated with AD.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Alzheimer’s disease</kwd>
<kwd>P7C3</kwd>
<kwd>neurodegeneration</kwd>
<kwd>neurogenesis</kwd>
<kwd>neuroprotection</kwd>
<kwd>TgF344-AD</kwd>
<kwd>depression</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>